在大麦中,的毒性耐受性源于流出输送器放大效应
Tim Sutton1, Ute Baumann, Julie Hayes
1Australian Centre for Plant Functional Genomics, School of Agriculture, Food and Wine, University of Adelaide, Waite Campus, Private Mail Bag 1, Glen Osmond, South Australia 5064, Australia. tim.sutton@acpfg.com.au
概括
科学家在阿尔及利亚大麦中发现了Bot1基因,提高了其对有毒水平的耐受性. 这一发现为改善全球受影响土壤的作物生产提供了潜力.
科学领域:
- 植物遗传学 植物遗传学
- 农业科学 农业科学
- 生物化学 生物化学
背景情况:
- 是作物必需的微量营养素,但土壤中的有毒水平在全球范围内限制了农业生产力.
- 开发对毒性的耐受性增强的作物对于受影响地区的粮食安全至关重要.
研究的目的:
- 确定阿尔及利亚大麦Sahara 3771.1.土地品种的优越毒性耐受性的遗传基础.
- 鉴定耐受性基因的功能和表达的特征.
主要方法:
- 高分辨率的基因映射以定位耐受性位置.
- 定量PCR用于评估基因拷贝数和转录水平.
- 酵母补充试验用于评估蛋白质功能.
主要成果:
- 被命名为Bot1的BOR1正义基因被确定为赋予毒性耐受性的关键基因.
- 撒哈拉3771的Bot1基因拷贝数量大约是不耐受基因型的四倍,Bot1转录水平也高于不耐受基因型.
- 来自撒哈拉3771的Bot1蛋白在酵母中表现出增强的耐受性.
结论:
- Bot1基因在大麦适应毒性的过程中起着至关重要的作用.
- 在大麦组织中Bot1的表达表明它参与调节的吸收和叶子的分泌.
- 了解Bot1的功能可以指导抗作物的发展.
相关概念视频
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...


